Printer Friendly

Amlodac.

Zydus Healthcare (SA) has launched Amlodac, the first generic amlodipine with the original besylate salt. Amlodac 5 mg and Amlodac 10 mg, packed as 30 tablets, will introduce a saving of at least 25% against the originator's product.

Amlodac adds to the current Zydus generic portfolio in South Africa (fluoxetine, paroxetine, tramadol, meloxicam and ranitidine) and will be the first of many early-to-market Zydus generics.

Amlodac is indicated for angina and mild to moderate hypertension. Recent revisions to hypertension treatment guidelines have clearly elevated the role of calcium-channel blockers, such as Amlodac. The ASCOT-BPLA trial has specifically demonstrated that a regimen starting with amlodipine besylate is better at reducing total cardiovascular events and procedures, fatal and non-fatal stroke, and the risk of new-onset diabetes.

Amlodac introduces a cost-effective treatment option for new hypertensives and the perfect generic switch for patients established on the original amlodipine besylate.

The Zydus product range is promoted in South Africa by Dr Reddy's.

Enquiries: Shirley Holmes, tel (011) 447-3215 , cell 082 375 3116.

[ILLUSTRATION OMITTED]
COPYRIGHT 2007 South African Medical Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Pulse: The heartbeat of the marketplace
Publication:CME: Your SA Journal of CPD
Article Type:Brief article
Geographic Code:6SOUT
Date:May 1, 2007
Words:170
Previous Article:Tri-Flora hails a new era in probiotics.
Next Article:New vaccine candidate for cervical cancer.
Topics:


Related Articles
How many times does your heart beat in one week?
Prevenar--pneumococcal conjugate vaccine.
Mouthulcer and LipRevive cold sore capsules.
Doctors' art.
New vaccine candidate for cervical cancer.
CVD duet offers benefits.
Synagis reduces recurrent wheeze.
Ranbaxy Laboratories finalises Be-Tabs acquisition.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters